On August 18th, Takeda China announced that Brigatinib(Alunbrig), Takeda’s innovative therapy for the treatment of ALK+ NSCLC(non-small cell lung cancer) , has been approved by the Hainan Provincial Drug Administration to be launched in the Boao LeCheng International Medical Tourism Pilot District, Hainan Free Trade Port, and the first patient has started her treatment at Boao Evergrande International Hospital.
ALK+ NSCLC is a dangerous, unique and relatively small subtype of lung cancer. China has around 35,000 new ALK+ NSCLC cases each year. Patients are generally young, and up to 30% of newly diagnosed patients may already be impacted by brain metastases, 75% of the patients will develop brain metastases within two years after the diagnosis, which greatly affects theses patients’ quality of life, and patients have urgent medical needs for innovative therapies.
As Takeda’s innovative therapy for ALK+ NSCLC patients, brigatinib is a potent and selective next-generation tyrosine kinase inhibitor (TKI) for treatment of adult patients with locally advanced or metastatic NSCLC that is anaplastic lymphoma kinase (ALK) positive. Brigatinib has been previously approved in the United States and Europe, and in January 2021, the new drug application of brigatinib in China was accepted by the National Medical Products Administration.
The Boao Lecheng Pilot District has been granted, by the State Council, the right to issue special licenses to import drugs and devices from oversea companies to meet medical needs. In 2020, Takeda and Lecheng Pilot District expanded the strategic partnership to explore more collaboration in healthcare innovation and medical technology, aiming to jointly improve patient access to innovative drugs. On July 9, 2021, Hainan Provincial Drug Administration approved the import of Brigatinib to Lecheng Pilot District under Takeda’s NPP, becoming Takeda China’s first product approved to enter the pilot district.